PMID- 30134995 OWN - NLM STAT- MEDLINE DCOM- 20190715 LR - 20190715 IS - 1868-7083 (Electronic) IS - 1868-7075 (Print) IS - 1868-7075 (Linking) VI - 10 IP - 1 DP - 2018 Aug 22 TI - Increased BDNF methylation in saliva, but not blood, of patients with borderline personality disorder. PG - 109 LID - 10.1186/s13148-018-0544-6 [doi] LID - 109 AB - BACKGROUND: The importance of epigenetic alterations in psychiatric disorders is increasingly acknowledged and the use of DNA methylation patterns as markers of disease is a topic of ongoing investigation. Recent studies suggest that patients suffering from Borderline Personality Disorder (BPD) display differential DNA methylation of various genes relevant for neuropsychiatric conditions. For example, several studies report differential methylation in the promoter region of the brain-derived neurotrophic factor gene (BDNF) in blood. However, little is known about BDNF methylation in other tissues. RESULTS: In the present study, we analyzed DNA methylation of the BDNF IV promoter in saliva and blood of 41 BPD patients and 41 matched healthy controls and found significant hypermethylation in the BPD patient's saliva, but not blood. Further, we report that BDNF methylation in saliva of BPD patients significantly decreased after a 12-week psychotherapeutic intervention. CONCLUSIONS: Providing a direct comparison of BDNF methylation in blood and saliva of the same individuals, our results demonstrate the importance of choice of tissue for the study of DNA methylation. In addition, they indicate a better suitability of saliva for the study of differential BDNF methylation in BPD patients. Further, our data appear to indicate a reversal of disease-specific alterations in BDNF methylation in response to psychotherapy, though further experiments are necessary to validate these results and determine the specificity of the effect. FAU - Thomas, Mara AU - Thomas M AD - Department of Psychiatry and Psychotherapy, University Hospital Tubingen, Calwerstr. 14, 72076, Tubingen, Germany. AD - Graduate Training Centre of Neuroscience, University of Tubingen, Tubingen, Germany. FAU - Knoblich, Nora AU - Knoblich N AD - Department of Psychiatry and Psychotherapy, University Hospital Tubingen, Calwerstr. 14, 72076, Tubingen, Germany. FAU - Wallisch, Annalena AU - Wallisch A AD - Department of Psychiatry and Psychotherapy, University Hospital Tubingen, Calwerstr. 14, 72076, Tubingen, Germany. FAU - Glowacz, Katarzyna AU - Glowacz K AD - Department of Psychiatry and Psychotherapy, University Hospital Tubingen, Calwerstr. 14, 72076, Tubingen, Germany. FAU - Becker-Sadzio, Julia AU - Becker-Sadzio J AD - Department of Psychiatry and Psychotherapy, University Hospital Tubingen, Calwerstr. 14, 72076, Tubingen, Germany. FAU - Gundel, Friederike AU - Gundel F AD - Department of Psychiatry and Psychotherapy, University Hospital Tubingen, Calwerstr. 14, 72076, Tubingen, Germany. FAU - Bruckmann, Christof AU - Bruckmann C AD - Department of Psychiatry and Psychotherapy, University Hospital Tubingen, Calwerstr. 14, 72076, Tubingen, Germany. FAU - Nieratschker, Vanessa AU - Nieratschker V AD - Department of Psychiatry and Psychotherapy, University Hospital Tubingen, Calwerstr. 14, 72076, Tubingen, Germany. vanessa.nieratschker@med.uni-tuebingen.de. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180822 PL - Germany TA - Clin Epigenetics JT - Clinical epigenetics JID - 101516977 RN - 0 (Biomarkers) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 7171WSG8A2 (BDNF protein, human) SB - IM MH - Adult MH - Biomarkers/metabolism MH - Borderline Personality Disorder/genetics/*therapy MH - Brain-Derived Neurotrophic Factor/*genetics MH - Case-Control Studies MH - CpG Islands MH - *DNA Methylation MH - Epigenesis, Genetic MH - Female MH - Humans MH - Male MH - Promoter Regions, Genetic MH - Saliva/*chemistry MH - Treatment Outcome MH - Young Adult PMC - PMC6106893 OTO - NOTNLM OT - BDNF OT - BPD OT - Biomarker OT - DBT OT - DNA methylation OT - Epigenetics OT - Saliva OT - Treatment outcome COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: All research was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from each subject prior to participation in the study. Ethical approval was obtained from the research ethics committees of the University of Tuebingen (project number 90/2015BO2). CONSENT FOR PUBLICATION: Not applicable COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/08/24 06:00 MHDA- 2019/07/16 06:00 PMCR- 2018/08/22 CRDT- 2018/08/24 06:00 PHST- 2018/05/29 00:00 [received] PHST- 2018/08/07 00:00 [accepted] PHST- 2018/08/24 06:00 [entrez] PHST- 2018/08/24 06:00 [pubmed] PHST- 2019/07/16 06:00 [medline] PHST- 2018/08/22 00:00 [pmc-release] AID - 10.1186/s13148-018-0544-6 [pii] AID - 544 [pii] AID - 10.1186/s13148-018-0544-6 [doi] PST - epublish SO - Clin Epigenetics. 2018 Aug 22;10(1):109. doi: 10.1186/s13148-018-0544-6.